Tactile Systems Technology, Inc. Reports Second Quarter 2023 Financial Results; Updates Full Year 2023 Outlook


MINNEAPOLIS, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2023.

Second Quarter 2023 Highlights:

  • Revenue increased 15% year-over-year to $68.3M
    • Lymphedema revenue increased 16%
    • Airway Clearance revenue increased 4%
  • Operating income of $2.1M, compared to operating loss of $4.1M
  • Net loss of $0.1M, compared to a net loss of $4.6M
  • Adjusted EBITDA of $6.1M, up from $1.7M
  • Cash Balance of $63.1M on June 30, 2023, compared to $55M on March 31, 2023
  • Raised full year 2023 financial guidance

Highlights Subsequent to Quarter End:

  • Sherri Ferstler appointed to the position of Senior Vice President of Sales, effective July 31, 2023
  • The Company’s existing credit agreement was amended on August 1, 2023 to extend the maturity date and improve terms

“We delivered total revenue growth of 15% year-over-year, significant improvements in both our GAAP and non-GAAP profitability and cash flow from operations of more than $13 million in the second quarter,” said Dan Reuvers, President and Chief Executive Officer of Tactile Medical. “Our revenue results were driven primarily by stronger-than-anticipated performance in our lymphedema product line – where we saw improvements in sales team productivity and strong customer adoption following the launch of our Entre® Plus system – with modest contributions from sales of our airway clearance products. In addition to our strong operating performance in the second quarter, we continued to make meaningful progress in strengthening our balance sheet.”

Mr. Reuvers continued: “We are raising our total revenue guidance today based on our strong performance over the first half of 2023. We look forward to driving continued progress with respect to our stated strategic objectives over the balance of 2023 as we position Tactile Medical for future growth and value creation.”

Second Quarter 2023 Financial Results

Total revenue in the second quarter of 2023 increased $8.7 million, or 14.6%, to $68.3 million, compared to $59.6 million in the second quarter of 2022. The increase in total revenue was attributable to an increase of $8.4 million, or 16.2%, in sales and rentals of the lymphedema product line, and an increase of $0.3 million, or 4.1%, in sales of the airway clearance product line, compared to the second quarter of 2022.

Gross profit in the second quarter of 2023 increased $5.1 million, or 11.7%, to $48.3 million, compared to $43.2 million in the second quarter of 2022. Gross margin was 70.7% of revenue, compared to 72.5% of revenue in the second quarter of 2022. Non-GAAP gross margin was 71.1% of revenue, compared to 73.0% of revenue in the second quarter of 2022.

Operating expenses in the second quarter of 2023 decreased $1.1 million, or 2.3%, to $46.2 million, compared to $47.3 million in the second quarter of 2022.

Operating income was $2.1 million in the second quarter of 2023, compared to an operating loss of $4.1 million in the second quarter of 2022. Non-GAAP operating income in the second quarter of 2023 was $3.6 million, compared to a non-GAAP operating loss of $1.8 million in the second quarter of 2022.

Other expense was $0.8 million in the second quarter of 2023, compared to $0.6 million in the second quarter of 2022.

Income tax expense was $1.3 million in the second quarter of 2023, compared to an income tax benefit of $20,000 in the second quarter of 2022.

Net loss in the second quarter of 2023 was $0.1 million, or $0.00 per diluted share, compared to $4.6 million, or $0.23 per diluted share, in the second quarter of 2022. Non-GAAP net income in the second quarter of 2023 was $1.0 million, compared to a non-GAAP net loss of $2.9 million in the second quarter of 2022.

Weighted average shares used to compute diluted net loss per share were 23.4 million and 20.0 million for the second quarters of 2023 and 2022, respectively.

Adjusted EBITDA was $6.1 million in the second quarter of 2023, compared to $1.7 million in the second quarter of 2022.

First Six Months 2023 Financial Results:

Total revenue for the six months ended June 30, 2023, increased $19.6 million, or 18.2%, to $127.2 million, compared to $107.6 million for the six months ended June 30, 2022. The increase in revenue was attributable to an increase of $17.5 million, or 18.9%, in sales and rentals of the lymphedema product line and an increase of $2.1 million, or 13.7%, in sales and rentals of the airway clearance product line.

Net loss for the six months ended June 30, 2023, was $2.0 million, or $0.09 per diluted share, compared to $20.2 million, or $1.01 per diluted share, for the six months ended June 30, 2022. Non-GAAP net income for the six months ended June 30, 2023, was $0.4 million, compared to a non-GAAP net loss of $11.4 million for the six months ended June 30, 2022.

Weighted average shares used to compute diluted net loss per share were 22.3 million and 20.0 million for the six months ended June 30, 2023 and 2022, respectively.

Adjusted EBITDA was $6.6 million in the six months ended June 30, 2023, compared to adjusted EBITDA loss of $0.9 million in the six months ended June 30, 2022.

Balance Sheet Summary

As of June 30, 2023, the Company had $63.2 million in cash and cash equivalents and $47.5 million of outstanding borrowings under its credit agreement, compared to $21.9 million in cash and cash equivalents and $49.0 million of outstanding borrowings under its credit agreement as of December 31, 2022.

2023 Financial Outlook

The Company now expects full year 2023 total revenue in the range of $274 million to $278 million, representing growth of approximately 11% to 13% year-over-year. The Company’s prior 2023 revenue guidance expectations called for total revenue in the range of $271 million to $275 million, representing growth of approximately 10% to 11.5% year-over-year.

Conference Call

Management will host a conference call at 5:00 p.m. Eastern Time on August 7th, 2023, to discuss the results of the quarter with a question-and-answer session. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13739727. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13739727. The webcast will be archived at investors.tactilemedical.com.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the impact of inflation, rising interest rates or a recession; the adequacy of the Company’s liquidity to pursue its business objectives; the Company’s ability to obtain reimbursement from third-party payers for its products; adverse economic conditions or intense competition; price increases for supplies and components; wage and component price inflation; loss of a key supplier; entry of new competitors and products; compliance with and changes in federal, state and local government regulation; loss or retirement of key executives, including prior to identifying a successor; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; the impacts of the COVID-19 pandemic on the Company’s business, financial condition and results of operations, and the Company’s inability to mitigate such impacts; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

This press release includes the non-GAAP financial measures of Adjusted EBITDA, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income (loss), and non-GAAP net income (loss), which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”).

Adjusted EBITDA in this release represents net income or loss, plus interest expense, net, or less interest income, net, less income tax benefit or plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, plus or minus the change in fair value of earn-out, and plus litigation defense costs. Non-GAAP gross profit in this release represents gross profit plus non-cash intangible amortization expense. Non-GAAP gross margin in this release represents non-GAAP gross profit divided by revenue. Non-GAAP operating income (loss) in this release represents operating income (loss) adjusted for non-cash intangible amortization expense, change in fair value of earn-out and litigation defense costs. Non-GAAP net income (loss) represents net income (loss) adjusted for non-cash intangible amortization expense, change in fair value of earn-out and litigation defense costs, and adjusted for the income tax effect on reconciling items. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP measures are included in this press release.

These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these measures principally as measures of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating plan and financial projections. The Company believes these measures are useful to investors as supplemental information and because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company also believes these non-GAAP financial measures are useful to its management and investors as a measure of comparative operating performance from period to period. In addition, Adjusted EBITDA is used as a performance metric in the Company’s compensation program.

The non-GAAP financial measures presented in this release should not be considered as an alternative to, or superior to, their respective GAAP financial measures, as measures of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and they should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating non-GAAP financial measures, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP financial measures should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using non-GAAP financial measures on a supplemental basis. The Company’s definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

Tactile Systems Technology, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
  June 30, December 31,
(In thousands, except share and per share data)  2023   2022 
Assets     
Current assets      
Cash and cash equivalents $63,212  $21,929 
Accounts receivable  46,553   54,826 
Net investment in leases  13,219   16,130 
Inventories  20,315   23,124 
Income taxes receivable  1,779    
Prepaid expenses and other current assets  4,480   3,754 
Total current assets  149,558   119,763 
Non-current assets      
Property and equipment, net  5,771   6,077 
Right of use operating lease assets  20,041   21,322 
Intangible assets, net  48,559   50,375 
Goodwill  31,063   31,063 
Accounts receivable, non-current  15,430   23,061 
Other non-current assets  3,306   3,335 
Total non-current assets  124,170   135,233 
Total assets $273,728  $254,996 
Liabilities and Stockholders' Equity      
Current liabilities      
Accounts payable $9,296  $9,984 
Note payable  2,968   2,968 
Earn-out, current  9,280   13,050 
Accrued payroll and related taxes  13,800   17,100 
Accrued expenses  5,166   9,240 
Income taxes payable     2,336 
Operating lease liabilities  2,529   2,500 
Other current liabilities  5,481   7,152 
Total current liabilities  48,520   64,330 
Non-current liabilities      
Revolving line of credit, non-current  24,941   24,916 
Note payable, non-current  19,495   20,979 
Accrued warranty reserve, non-current  1,957   2,207 
Income taxes payable, non-current  446   298 
Operating lease liabilities, non-current  19,606   20,866 
Total non-current liabilities  66,445   69,266 
Total liabilities  114,965   133,596 
       
Stockholders’ equity:      
Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of June 30, 2023 and December 31, 2022      
Common stock, $0.001 par value, 300,000,000 shares authorized; 23,458,302 shares issued and outstanding as of June 30, 2023; 20,252,677 shares issued and outstanding as of December 31, 2022  23   20 
Additional paid-in capital  170,347   131,001 
Accumulated deficit  (11,607)  (9,621)
Total stockholders’ equity  158,763   121,400 
Total liabilities and stockholders’ equity $273,728  $254,996 



Tactile Systems Technology, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
             
             
  Three Months Ended Six Months Ended
  June 30, June 30,
(In thousands, except share and per share data)  2023   2022   2023   2022 
Revenue            
Sales revenue $59,802  $51,265  $112,593  $92,435 
Rental revenue  8,537   8,380   14,592   15,188 
Total revenue  68,339   59,645   127,185   107,623 
Cost of revenue            
Cost of sales revenue  16,865   13,810   31,507   25,890 
Cost of rental revenue  3,175   2,612   5,911   4,648 
Total cost of revenue  20,040   16,422   37,418   30,538 
Gross profit            
Gross profit - sales revenue  42,937   37,455   81,086   66,545 
Gross profit - rental revenue  5,362   5,768   8,681   10,540 
Gross profit  48,299   43,223   89,767   77,085 
Operating expenses            
Sales and marketing  28,206   28,822   54,508   52,752 
Research and development  1,833   1,849   4,066   3,369 
Reimbursement, general and administrative  14,991   14,894   30,425   31,111 
Intangible asset amortization and earn-out  1,211   1,745   2,516   8,841 
Total operating expenses  46,241   47,310   91,515   96,073 
Income (loss) from operations  2,058   (4,087)  (1,748)  (18,988)
Other expense  (838)  (573)  (1,831)  (1,029)
Income (loss) before income taxes  1,220   (4,660)  (3,579)  (20,017)
Income tax expense (benefit)  1,320   (20)  (1,593)  191 
Net loss $(100) $(4,640) $(1,986) $(20,208)
Net loss per common share            
Basic $0.00  $(0.23) $(0.09) $(1.01)
Diluted $0.00  $(0.23) $(0.09) $(1.01)
Weighted-average common shares used to compute net loss per common share            
Basic  23,352,530   20,024,798   22,323,856   19,961,999 
Diluted  23,352,530   20,024,798   22,323,856   19,961,999 



Tactile Systems Technology, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
   
  Six Months Ended June 30,
(In thousands)  2023   2022 
Cash flows from operating activities      
Net loss $(1,986) $(20,208)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation and amortization  3,269   3,015 
Deferred income taxes     94 
Stock-based compensation expense  3,831   5,121 
Loss on disposal of property and equipment and intangibles  3    
Change in fair value of earn-out liability  1,230   7,550 
Changes in assets and liabilities, net of acquisition:      
Accounts receivable  8,273   321 
Net investment in leases  2,911   (864)
Inventories  2,809   (753)
Income taxes  (3,967)  (55)
Prepaid expenses and other assets  (697)  1,925 
Right of use operating lease assets  50   106 
Accounts receivable, non-current  7,631   (2,496)
Accounts payable  (696)  4,087 
Accrued payroll and related taxes  (3,300)  5 
Accrued expenses and other liabilities  (5,954)  1,252 
Net cash provided by (used in) operating activities  13,407   (900)
Cash flows from investing activities      
Purchases of property and equipment  (1,043)  (331)
Intangible assets expenditures  (99)  (85)
Net cash used in investing activities  (1,142)  (416)
Cash flows from financing activities      
Payment on earn-out  (5,000)   
Payments on note payable  (1,500)  (4,500)
Payments of deferred debt issuance costs     (39)
Proceeds from exercise of common stock options  11   152 
Proceeds from the issuance of common stock from the employee stock purchase plan  882   824 
Proceeds from issuance of common stock at market  34,625    
Net cash provided by (used in) financing activities  29,018   (3,563)
Net increase (decrease) in cash and cash equivalents  41,283   (4,879)
Cash and cash equivalents – beginning of period  21,929   28,229 
Cash and cash equivalents – end of period $63,212  $23,350 
       
Supplemental cash flow disclosure      
Cash paid for interest $1,925  $448 
Cash paid for taxes $2,415  $28 
Capital expenditures incurred but not yet paid $8  $ 


The following table summarizes revenue by product line for the three and six months ended June 30, 2023 and 2022:

             
  Three Months Ended Six Months Ended
  June 30, June 30,
(In thousands)  2023   2022   2023   2022 
Revenue            
Lymphedema products $59,999  $51,634  $109,751  $92,288 
Airway clearance products  8,340   8,011   17,434   15,335 
Total $68,339  $59,645  $127,185  $107,623 
             
Percentage of total revenue            
Lymphedema products  88%  87%  86%  86%
Airway clearance products  12%  13%  14%  14%
Total  100%  100%  100%  100%


The following table contains a reconciliation of GAAP gross profit and margin to non-GAAP gross profit and margin:

Tactile Systems Technology, Inc.
Reconciliation of Gross Profit and Margin to Non-GAAP Gross Profit and Margin
(Unaudited)
                 
  Three Months Ended Six Months Ended
  June 30,June 30,
(Dollars in thousands) 2023 2022 2023 2022
Gross profit, as reported $48,299  $43,223  $89,767  $77,085 
Gross margin, as reported  70.7%  72.5%  70.6%  71.6%
Reconciling items:                
Non-cash intangible amortization expense $315  $311  $629  $621 
Non-GAAP gross profit $48,614  $43,534  $90,396  $77,706 
Non-GAAP gross margin  71.1%  73.0%  71.1%  72.2%


The following table contains a reconciliation of GAAP operating income (loss) to non-GAAP operating income (loss):

Tactile Systems Technology, Inc.
Reconciliation of GAAP Operating Income (Loss) to Non-GAAP Operating Income (Loss)
(Unaudited)
              
  Three Months Ended Six Months Ended
  June 30,June 30,
(Dollars in thousands) 2023 2022 2023 2022
GAAP operating income (loss) $2,058  $(4,087) $(1,748) $(18,988)
Reconciling items:             
Non-cash intangible amortization expense impacting gross profit $315  $311  $629  $621 
Non-cash intangible amortization expense impacting operating expenses  641   645   1,286   1,291 
Change in fair value of earn-out  570   1,100   1,230   7,550 
Litigation defense costs     245      2,349 
Non-GAAP operating income (loss): $3,584  $(1,786) $1,397  $(7,177)
Non-GAAP operating margin  5.2%  (3.0)%  1.1%  (6.7)%


The following table contains a reconciliation of GAAP net loss to non-GAAP net income (loss):

Tactile Systems Technology, Inc.
Reconciliation of GAAP Net Loss to Non-GAAP Net Income (Loss)
(Unaudited)
             
  Three Months Ended Six Months Ended
  June 30,June 30,
(Dollars in thousands) 2023 2022 2023 2022
GAAP net loss $(100) $(4,640) $(1,986) $(20,208)
Reconciling items:            
Non-cash intangible amortization expense impacting gross profit $315  $311  $629  $621 
Non-cash intangible amortization expense impacting operating expenses  641   645   1,286   1,291 
Change in fair value of earn-out  570   1,100   1,230   7,550 
Litigation defense costs     245      2,349 
Income tax expense on reconciling items*  (382)  (575)  (786)  (2,953)
Non-GAAP net income (loss) $1,044  $(2,914) $373  $(11,350)
* The effect of income tax on the reconciling items is estimated using the Company's effective statutory tax rate.


The following table contains a reconciliation of net loss to Adjusted EBITDA for the three and six months ended June 30, 2023 and 2022, as well as the dollar and percentage change between the comparable periods:

Tactile Systems Technology, Inc.
Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA
(Unaudited)
                         
  Three Months Ended Increase Six Months Ended Increase
  June 30, (Decrease) June 30, (Decrease)
(Dollars in thousands)  2023   2022  $ %  2023   2022  $ %
Net loss $(100) $(4,640) $4,540  (98)% $(1,986) $(20,208) $18,222  (90)%
Interest expense, net  838   584   254  43 %  1,831   1,040   791  76 
Income tax (benefit) expense  1,320   (20)  1,340  N.M. %  (1,593)  191   (1,784) N.M. %
Depreciation and amortization  1,640   1,508   132  9 %  3,269   3,015   254  8 %
Stock-based compensation  1,808   2,892   (1,084) (37)%  3,831   5,121   (1,290) (25)%
Change in fair value of earn-out  570   1,100   (530) (48)  1,230   7,550   (6,320) (84)
Litigation defense costs     245   (245) (100)%     2,349   (2,349) (100)%
Adjusted EBITDA $6,076  $1,669  $4,407  N.M. % $6,582  $(942) $7,524  N.M. %

 

Contact Data